These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 32641471)

  • 1. Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19.
    Yip TC; Lui GC; Wong VW; Chow VC; Ho TH; Li TC; Tse YK; Hui DS; Chan HL; Wong GL
    Gut; 2021 Apr; 70(4):733-742. PubMed ID: 32641471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver Biochemistries in Hospitalized Patients With COVID-19.
    Bloom PP; Meyerowitz EA; Reinus Z; Daidone M; Gustafson J; Kim AY; Schaefer E; Chung RT
    Hepatology; 2021 Mar; 73(3):890-900. PubMed ID: 32415860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 and hepatitis.
    Trevenzoli M; Guarnaccia A; Alberici I; Fassan M; Di Meco E; Farinati F; Cattelan AM
    J Gastrointestin Liver Dis; 2020 Sep; 29(3):473-475. PubMed ID: 32919428
    [No Abstract]   [Full Text] [Related]  

  • 4. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study.
    Weber S; Hellmuth JC; Scherer C; Muenchhoff M; Mayerle J; Gerbes AL
    Gut; 2021 Oct; 70(10):1925-1932. PubMed ID: 33514597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic changes in liver function parameters in patients with coronavirus disease 2019: a multicentre, retrospective study.
    Zeng QL; Yu ZJ; Ji F; Li GM; Zhang GF; Xu JH; Lin WB; Zhang GQ; Li GT; Cui GL; Wang FS
    BMC Infect Dis; 2021 Aug; 21(1):818. PubMed ID: 34399709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network.
    Hundt MA; Deng Y; Ciarleglio MM; Nathanson MH; Lim JK
    Hepatology; 2020 Oct; 72(4):1169-1176. PubMed ID: 32725890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pattern of liver injury in adult patients with COVID-19: a retrospective analysis of 105 patients.
    Wang Q; Zhao H; Liu LG; Wang YB; Zhang T; Li MH; Xu YL; Gao GJ; Xiong HF; Fan Y; Cao Y; Ding R; Wang JJ; Cheng C; Xie W
    Mil Med Res; 2020 Jun; 7(1):28. PubMed ID: 32507110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Hosseini FS; Malektojari A; Ghazizadeh S; Hassaniazad M; Davoodian P; Dadvand H; Nikpoor AR; Nikoofal-Sahlabadi S; Kahoori S; Sepandi M; Hassanipour S; Fathalipour M
    Trials; 2021 Jan; 22(1):4. PubMed ID: 33397429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
    Kocayiğit H; Özmen Süner K; Tomak Y; Demir G; Yaylacı S; Dheir H; Güçlü E; Erdem AF
    J Clin Pharm Ther; 2021 Apr; 46(2):454-459. PubMed ID: 33128482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19.
    Yip TC; Wong VW; Lui GC; Chow VC; Tse YK; Hui VW; Liang LY; Chan HL; Hui DS; Wong GL
    Hepatology; 2021 Oct; 74(4):1750-1765. PubMed ID: 33961298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
    Hung IF; Lung KC; Tso EY; Liu R; Chung TW; Chu MY; Ng YY; Lo J; Chan J; Tam AR; Shum HP; Chan V; Wu AK; Sin KM; Leung WS; Law WL; Lung DC; Sin S; Yeung P; Yip CC; Zhang RR; Fung AY; Yan EY; Leung KH; Ip JD; Chu AW; Chan WM; Ng AC; Lee R; Fung K; Yeung A; Wu TC; Chan JW; Yan WW; Chan WM; Chan JF; Lie AK; Tsang OT; Cheng VC; Que TL; Lau CS; Chan KH; To KK; Yuen KY
    Lancet; 2020 May; 395(10238):1695-1704. PubMed ID: 32401715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice.
    Levy C; Lassailly G; Parmentier E; Duburcq T; Mathurin P; Poissy J
    Am J Gastroenterol; 2020 Oct; 115(10):1716-1718. PubMed ID: 32858566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors of liver injury in patients with coronavirus disease 2019 in Jiangsu, China: A retrospective, multi-center study.
    Wang J; Zhu L; Xue L; Liu L; Yan X; Yan X; Huang S; Zhang B; Xu T; Li C; Ji F; Ming F; Zhao Y; Cheng J; Shao H; Chen K; Zhao XA; Sang D; Zhao H; Guan X; Chen X; Chen Y; Liu J; Huang R; Zhu C; Wu C
    J Med Virol; 2021 Jun; 93(6):3305-3311. PubMed ID: 33174624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Features of Patients Infected With Coronavirus Disease 2019 With Elevated Liver Biochemistries: A Multicenter, Retrospective Study.
    Fu Y; Zhu R; Bai T; Han P; He Q; Jing M; Xiong X; Zhao X; Quan R; Chen C; Zhang Y; Tao M; Yi J; Tian D; Yan W
    Hepatology; 2021 Apr; 73(4):1509-1520. PubMed ID: 32602604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of liver test abnormalities on the prognosis of COVID-19.
    Medetalibeyoglu A; Catma Y; Senkal N; Ormeci A; Cavus B; Kose M; Bayramlar OF; Yildiz G; Akyuz F; Kaymakoglu S; Tukek T
    Ann Hepatol; 2020; 19(6):614-621. PubMed ID: 32920162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.